KKR:NYSE

KKR & Co. Inc.

Data as of 2026-03-10 - not real-time

$90.94

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

KKR is trading at $90.94, well below its 20‑day SMA of 97.50 and the 50‑day SMA of 113.03, with the price sitting just above the computed support level of $84.52. The RSI of 35.5 signals that the stock is approaching oversold territory, while the MACD histogram has turned positive, indicating a tentative bullish reversal despite a broader bearish trend and a high 30‑day volatility of 57.4%. The equity carries a beta of 1.85, suggesting amplified moves relative to the market, and the fear‑greed index is at “Extreme Greed,” reflecting strong investor appetite despite the recent 23% price decline over the past month.
Fundamentally, KKR posted an impressive 76% revenue growth year‑over‑year, with operating margins above 33% and a solid cash pile of $42.6 bn, though it also holds $56.0 bn of debt. The current PE of 38.9 is far above the industry average of 17.4, but the forward PE of 11.45 and a mean analyst target of $140.35 point to significant upside (≈54%). Recent news highlights a strong Q4 2025 earnings beat, a director’s $4.7 m share purchase, and rumors of a multibillion‑dollar exit from CoolIT Systems, all of which bolster the “buy‑the‑dip” narrative from Wall Street analysts.

Trading Recommendations

Short Term

< 1 year
hold
Conviction: 5/10

Key Factors

  • Price hovering just above technical support
  • Bearish SMA alignment and high short‑term volatility
  • Oversold RSI suggesting limited further downside

Medium Term

1–3 years
buy
Conviction: 7/10

Key Factors

  • Forward PE of 11.45 indicating cheap valuation relative to earnings growth
  • Analyst consensus (19 analysts) rating the stock as a buy with a $136‑$140 target
  • Potential multibillion‑dollar exit from CoolIT providing a catalyst

Long Term

> 3 years
buy
Conviction: 8/10

Key Factors

  • Strong cash generation and diversified global asset base
  • Sustainable dividend yield with a low payout ratio
  • Continued strategic acquisitions and exits driving long‑term earnings expansion

Key Metrics & Analysis

Financial Health

Revenue Growth76.30%
Profit Margin9.24%
P/E Ratio38.9
ROE8.56%
ROA1.60%
Debt/Equity68.61
P/B Ratio2.9
Op. Cash Flow$477.8M
Industry P/E17.4

Technical Analysis

TrendBearish
RSI35.5
Support$84.52
Resistance$109.53
MA 20$97.50
MA 50$113.03
MA 200$126.92
MACDBullish
VolumeIncreasing
Fear & Greed Index75.89

Valuation

Target Price$140.35
Upside/Downside54.33%
GradeUndervalued
TypeGrowth
Dividend Yield0.81%

Risk Assessment

Beta1.85
Volatility57.43%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.